Earnings

Medpace Holdings Raises FY2026 GAAP EPS Guidance from $17.25-$17.95 to $17.97-$18.32 vs $17.60 Est; Narrows FY2026 Sales Guidance from $2.805B-$2.885B to $2.835B-$2.855B vs $2.851B Est

Oct 21, 2026 · 04:19 PM ET· updated 1h ago

Medpace Holdings (NASDAQ:MEDP) raises FY2026 GAAP EPS guidance from $17.25-$17.95 to $17.97-$18.32 vs $17.60 analyst estimate. Narrows FY2026 sales outlook from $2.805 billion-$2.885 billion to $2.835 billion-$2.855

Why It Matters

Medpace raised its profit forecast for next year, now expecting higher earnings than analysts thought. The company narrowed its sales range, showing more confidence about what it will earn.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MEDP651.50

+29.07 (+4.67%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.